Navigation Links
GeoVax Labs, Inc. Reports Fourth Quarter and Year-End 2008 Financial Results
Date:3/12/2009

* In February 2009, GeoVax announced the first injections in its Phase 2a Human Clinical Vaccine Trial for its candidate HIV/AIDS vaccine. The trial, designated HVTN 205, is being conducted by the HVTN (already provided definition above). The HVTN, funded and supported by the National Institutes of Allergy and Infectious Diseases (NIAID), is the largest worldwide clinical trials network dedicated to the development and testing of HIV/AIDS vaccines. The HVTN has sponsored over 80 Phase 1 trials for the initial evaluation of safety and immunogenicity of candidate HIV/AIDS vaccines. Of these, only five have progressed to Phase 2 trials since 1992. Progressing to Phase 2 was a significant achievement for GeoVax. First injections for the Phase 2a trial were conducted at the HVTN network sites at the University of Alabama, Birmingham, and Vanderbilt University, Nashville. The trial will include a total of 225 volunteers (150 vaccine recipients and 75 placebo recipients) and take place at 13 HVTN sites: 11 in North America and 2 in South America. Sites in the United States include Emory University, Atlanta; Harvard Medical School, Brigham & Women's Hospital and Harvard-Fenway Hospital in Boston; Vanderbilt University, Nashville; University of Rochester; Fred Hutchinson Cancer Research Center, Seattle; the San Francisco Department of Public Health; University of Alabama, Birmingham, and sites at Columbia University, Union Square, and the Bronx in New York City. In South America, participants are to be enrolled in Peru at sites in Iquitos and Miraflores (Lima). * In February 2009, GeoVax presented a corporate update at the Eleventh Annual BIO CEO & Investor Conference 2009, held in New York
'/>"/>
SOURCE GeoVax Labs, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. GeoVax Update Provided at the BIO CEO & Investor Conference 2009
2. GeoVax to Webcast Its Presentation at the BIO CEO & Investor 2009 Conference
3. GeoVax to Present at the BIO CEO & Investor Conference 2009
4. GeoVax Labs, Inc. Announces Third Quarter 2008 Financial Results and Provides Operational Update
5. GeoVaxs DNA and MVA Vaccines Shipped to HIV Vaccine Trials Network for Use in the Upcoming Phase 2a Trial
6. GeoVax Presents Data at AIDS Vaccine 2008 Conference
7. GeoVax Labs, Inc. Information To Be Available Through Standard & Poors Market Access Program
8. GeoVax Labs, Inc. Announces Six Month Financial Results and Provides Operational Update
9. GeoVax Further Strengthens Management Team
10. U.S. Government Awards $15 Million Grant to GeoVax Labs HIV/AIDS Vaccine Program
11. GeoVax Labs, Inc. Second Quarter Financial Results and Operational Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... BCC Research ( http://www.bccresearch.com ) reveals in its new ... GLOBAL MARKETS , the global market for digital polymerase ... 2013. This is estimated to grow to $490 billion ... (CAGR) of 28.6%. , New digital PCR technology has ... the broader PCR field. The opportunities presented by this ...
(Date:7/11/2014)... AZ (PRWEB) July 11, 2014 ... device company specializing in the soft tissue reconstruction ... All-Suture Anchor System for surgeries involving the shoulder ... fixation through a novel, inserter-controlled deployment method. The ... to partial deployment, anchor pull-out, or anchor displacement ...
(Date:7/10/2014)... Understanding the need for better quality and higher ... that currently exists in this area, ChanTest has recently ... validated ion channel and GPCR cell lines. ChanTest’s ... channels control many critical physiological functions throughout the body. ... to treat a variety of human diseases. , ...
(Date:7/10/2014)... Angeles, CA (PRWEB) July 10, 2014 ... and Bioanalytical techniques during 18-20 August, 2014 at Double ... critically review the recent developments in Analytical & Bioanalytical ... the globe. , Speaking on this occasion, Dr. Srinubabu ... Analytica Acta conference is a remarkable one in ...
Breaking Biology Technology:Global Market for Digital Polymerase Chain Reaction Technology to Reach $490 Billion by 2018; Equipment Sector Accounts for the Fastest Growing Segment With 33% CAGR 2Global Market for Digital Polymerase Chain Reaction Technology to Reach $490 Billion by 2018; Equipment Sector Accounts for the Fastest Growing Segment With 33% CAGR 3Cayenne Medical Launches SureLock™ All-Suture Anchor System for Shoulder and Extremity Surgery 2Cayenne Medical Launches SureLock™ All-Suture Anchor System for Shoulder and Extremity Surgery 3Leader in Ion Channel Research Announces Newly Validated and Re-Engineered Cells 2Leader in Ion Channel Research Announces Newly Validated and Re-Engineered Cells 3A Critical Review of Analytical Techniques for Improved Living Standards 2A Critical Review of Analytical Techniques for Improved Living Standards 3A Critical Review of Analytical Techniques for Improved Living Standards 4
... CITY, Calif. , June 17 OncoMed Pharmaceuticals, Inc. ... global strategic alliance to discover, develop and commercialize novel anti-cancer stem ... a subset of tumor cells believed to play a significant role ... , , ...
... Institute have developed a new, ultra-simple method for ... of a meter thick. The process, which requires ... surface including silicon wafers, could have important implications ... assistant professor in the Department of Physics, Applied ...
... MD ... the functional relevance of a drug treatment on the heart following direct coronary flow ... ... MD Biosciences , a Preclinical Contract Research Organization (CRO), offers in vivo models for ...
Cached Biology Technology:OncoMed Pharmaceuticals and Bayer Schering Pharma Announce Strategic Alliance to Develop Anti-Cancer Stem Cell Therapeutics 2OncoMed Pharmaceuticals and Bayer Schering Pharma Announce Strategic Alliance to Develop Anti-Cancer Stem Cell Therapeutics 3OncoMed Pharmaceuticals and Bayer Schering Pharma Announce Strategic Alliance to Develop Anti-Cancer Stem Cell Therapeutics 4OncoMed Pharmaceuticals and Bayer Schering Pharma Announce Strategic Alliance to Develop Anti-Cancer Stem Cell Therapeutics 5Researchers develop ultra-simple method for creating nanoscale gold coatings 2MD Biosciences Offers Occlusion-induced Myocardial Infarct Model for Investigating the Cardio-protection of a Drug Treatment in the Event of Ischemia/reperfusion Injury 2
(Date:7/10/2014)... and other major cities in New Mexico, nearly every ... wastewater rather than precious potable water supplies. Across the ... all golf courses receive treated effluent. Reusing the effluent ... golf courses and homeowners alike fertilize their lawns during ... nitrate. A New Mexico State University turfgrass expert has ...
(Date:7/10/2014)... 2014  Unisys Corporation,s (NYSE: UIS ) subsidiary ... today announced that it has been selected by the Dutch ... new Basic Provision Biometrics solution for penitentiaries across ... contract with a solution based on its open standards-based ... the contract is up to seven years, with the new ...
(Date:7/10/2014)... Fingerprint Cards, (FPC,s) new mobile touch sensor FPC1021 ... Top 5 smartphone OEM has selected FPC1021 for a flagship ... 2014.   FPC is proud to announce this ... a planned date for the start of mass production in ... of 3 million units. The Chinese OEM wants to remain ...
Breaking Biology News(10 mins):'Tailored' water -- the latest in lawn care 2Unisys Delivers New Basic Provision Biometrics Solution to Dutch Custodial Institutions Service 2Unisys Delivers New Basic Provision Biometrics Solution to Dutch Custodial Institutions Service 3FPC Wins DW for 1021 Touch Sensor for Flagship Smartphone from Chinese Top 5 Smartphone OEM 2
... InvenTeams were among more than a dozen teams from ... a White House Science Fair. The fair celebrates the ... and math (STEM) competitions, including students from the Cesar ... Oak Ridge High School InvenTeam in Oak Ridge, Tennessee ...
... Harbor, NY -- A team co-led by neuroscientists at Cold ... on circuitry underlying the olfactory system in mammals, giving us ... some of its most amazing feats. It ... instance, can tell the difference between two quite similar odors ...
... , Tampa, Fla. (October 18, 2010) Two research ... Medicine (Okayama, Japan) have reported breakthrough studies in ... technical breakthrough in creating induced pluripotent stem cells ... vitro had "implications for overcoming immunological rejection." Whereas ...
Cached Biology News:White House Science Fair showcases Lemelson-MIT InvenTeams 2White House Science Fair showcases Lemelson-MIT InvenTeams 3White House Science Fair showcases Lemelson-MIT InvenTeams 4Optical technique reveals unnexpected complexity in mammalian olfactory coding 2Optical technique reveals unnexpected complexity in mammalian olfactory coding 3Optical technique reveals unnexpected complexity in mammalian olfactory coding 4Japanese researchers report on liver transplantation studies using animal and iPS cells 2
... The new Adept CE 4100 high ... superb flow precision, with software drive compensation, ... from 0.001-10mL/min are selectable in 0.001mL steps. ... are inert and bio-compatible., Pumps may be ...
... angle system, 220-240 V, is used to resolve ... fragments by pulsed field gel electrophoresis (PFGE). The ... pump, 14 x 13 cm casting stand with ... thick comb, screened cap, disposable plug molds, 12 ...
... Immuno-Blot PVDF membrane and filter paper ... PVDF membrane and two sheets of thick ... blotting membrane and filter paper sandwich. These ... high binding capacity immunoblotting fit Ready Gel-sized ...
... fromStreptomyces griseolusthat inhibits protein synthesis. Acts ... eukaryote ribosomes. Reported to induce apoptosis ... promyelocytic leukemia cells, Jurkat cells, ventricular ... intracellular signals and immediate early gene ...
Biology Products: